SCHEMBL17582736

SCHEMBL17582736

CC(C)(C)n1c(NC(=O)C[C@](C)(O)c2ccccc2)nc2ccc(C#N)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACSS2 Q9NR19 7/20 0.48
RORC P51449 1/20 0.38
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RPS6KA2 Q15349 1/20 0.37
SLC22A12 Q96S37 1/20 0.36
CCR9 P51686 1/20 0.36
ALB P02768 1/20 0.36
OPRK1 P41145 2/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
LMNA P02545 2/20 0.35
USP2 O75604 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17582741 1.00 ACSS2 (0.48) ACSS2RORCALDH1A1KDM4EGLA
SCHEMBL17582856 1.00 ACSS2 (0.48) ACSS2RORCALDH1A1KDM4EGLA
SCHEMBL18791849 0.92 ACSS2 (0.45) ACSS2RORCALDH1A1KDM4EGLA
SCHEMBL18791850 0.92 ACSS2 (0.45) ACSS2RORCALDH1A1KDM4EGLA
SCHEMBL20110978 0.92 ACSS2 (0.45) ACSS2RORCALDH1A1KDM4EGLA
SCHEMBL21354748 0.87 ACSS2 (0.51) ACSS2RORCOPRK1OPRM1OPRD1
SCHEMBL30315295 0.87 ACSS2 (0.51) ACSS2RORCOPRK1OPRM1OPRD1
SCHEMBL30315309 0.86 ACSS2 (0.49) ACSS2RORCRPS6KA2OPRK1OPRM1
SCHEMBL21354585 0.86 ACSS2 (0.49) ACSS2RORCRPS6KA2OPRK1OPRM1
SCHEMBL17586626 0.85 ACSS2 (0.38) ACSS2RPS6KA2LMNASMN1; SMN2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2025-07-08 US disclosed
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2024-09-12 US disclosed
EP-4289822-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (US) 2023-12-13 EP disclosed
EP-4289822-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (US) 2023-12-13 EP disclosed
EP-3572405-B9 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2023-12-06 EP disclosed
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2023-12-05 US disclosed
US-11724990-B2 Kv7 channel activators compositions and methods of use BIOHAVEN THERAPEUTICS LTD. (VG) 2023-08-15 US disclosed
EP-3572405-B1 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2023-07-26 EP disclosed
EP-3572405-B1 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2023-07-26 EP disclosed
US-20210188782-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2021-06-24 US disclosed
US-20180148419-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2018-05-31 US disclosed
US-20180148419-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2018-05-31 US disclosed
WO-2018081825-A1 BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2018-05-03 WO disclosed
US-9914708-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KNOPP BIOSCIENCES LLC (US) 2018-03-13 US disclosed
US-9914708-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KNOPP BIOSCIENCES LLC (US) 2018-03-13 US disclosed
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-04-27 US disclosed
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-04-27 US disclosed
US-9481653-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KNOPP BIOSCIENCES LLC (US) 2016-11-01 US disclosed
US-9481653-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KNOPP BIOSCIENCES LLC (US) 2016-11-01 US disclosed
US-20160075663-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 ACSS2 928/4885RORC 3620/4885ALDH1A1 2106/4885
US-11724990-B2 Kv7 channel activators compositions and methods of use KCNA7, KCNK17, KCNAB1 ACSS2 2521/4885RORC 2225/4885ALDH1A1 3093/4885
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNK2 ACSS2 566/4885RORC 3795/4885ALDH1A1 1492/4885
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 ACSS2 928/4885RORC 3620/4885ALDH1A1 2106/4885
US-20180148419-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 ACSS2 928/4885RORC 3620/4885ALDH1A1 2106/4885
US-20160075663-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 ACSS2 928/4885RORC 3620/4885ALDH1A1 2106/4885
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 ACSS2 957/4885RORC 3771/4885ALDH1A1 2065/4885
US-20210188782-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 ACSS2 928/4885RORC 3620/4885ALDH1A1 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.